Abraxane
Abraxane is an originator product from Bristol-Myers Squibb SA and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 332.10 to CHF 332.10 depending on the pack; the patient co-payment is 40 per cent plus the deductible.
Core data
- Authorisation holder
- Bristol-Myers Squibb SA
- ATC code
- L01CD01
- IT group
- 07.16.10 Cytostatica
- Active substances
- Paclitaxelum (Paclitaxelum-Albuminum)
- Preparation type
- Originator product
- On the SL since
- 01/04/2015
- Last price change
- 01/12/2023
- Co-payment
- 40%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Trockensub 100 mg | Durchstf 1 Stk | CHF 296.98 | CHF 332.10 | 01/04/2015 | A | 7680631820012 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
In Kombination mit Gemcitabin, für die Erstlinienbehandlung von Patienten mit lokal fortgeschrittenem, nicht resezierbarem oder metastasiertem Adenokarzinom des Pankreas.
Behandlung des metastasierenden Mammakarzinoms
Nach vorgängiger Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.
Behandlung des metastasierenden Mammakarzinoms nach Versagen einer Chemotherapie oder Rezidiv innert 6 Monaten nach adjuvanter Chemotherapie. In der Vortherapie muss ein Anthrazyklin enthalten gewesen sein, es sei denn, es bestand eine Kontraindikation. Die Therapie muss als Monotherapie verabreicht werden. Eine Kombination mit Biologika oder antihormoneller Therapie ist nicht möglich. Abraxane darf nicht als Alternative für andere Paclitaxel-Formulierungen verwendet werden, es sei denn die Behandlung mit anderen Paclitaxel-Formulierungen ist ungeeignet.
More preparations in this group
FAQ
Is Abraxane covered by Swiss health insurance?
Yes, but only under conditions. Abraxane is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Abraxane cost in Switzerland?
The public price is the maximum price set by the FOPH and for Abraxane ranges from CHF 332.10 to CHF 332.10 per pack. The ex-factory price ranges from CHF 296.98 to CHF 296.98. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages